Eversept Partners, LP Tricida, Inc. Transaction History

Eversept Partners, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 13, 2020	SELL	$29.6 - $43.71 $1.94 Million - $2.87 Million	-65,568 Closed	0 $0
Q3 2019 Nov 08, 2023	SELL	$29.87 - $42.22 $657,140 - $928,840	-22,000 Reduced 25.12%	65,568 $2.02 Million
Q3 2019 Nov 13, 2019	SELL	$29.87 - $42.22 $657,140 - $928,840	-22,000 Reduced 25.12%	65,568 $2.02 Million
Q2 2019 Nov 08, 2023	BUY	$31.16 - $39.46 $1.19 Million - $1.5 Million	38,060 Added 76.88%	87,568 $3.46 Million
Q2 2019 Aug 13, 2019	BUY	$31.16 - $39.46 $1.19 Million - $1.5 Million	38,060 Added 76.88%	87,568 $3.46 Million
Q1 2019 Nov 08, 2023	BUY	$19.96 - $38.62 $179,360 - $347,039	8,986 Added 22.18%	49,508 $1.91 Million
Q1 2019 May 14, 2019	BUY	$19.96 - $38.62 $179,360 - $347,039	8,986 Added 22.18%	49,508 $1.91 Million
Q4 2018 Nov 08, 2023	BUY	$23.57 - $32.33 $386,548 - $530,212	16,400 Added 67.99%	40,522 $955,000
Q4 2018 Feb 13, 2019	BUY	$23.57 - $32.33 $386,548 - $530,212	16,400 Added 67.99%	40,522 $956,000
Q3 2018 Nov 08, 2023	BUY	$22.5 - $39.35 $542,745 - $949,200	24,122 New	24,122 $736,000
Q3 2018 Nov 14, 2018	BUY	$22.5 - $39.35 $542,745 - $949,200	24,122 New	24,122 $737,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Eversept Partners, LP with notifications on news.